EU Clears AZ's SERD Camizestrant, as FDA Review Drags On

EU clears AZ's SERD camizestrant, as FDA review drags on

AstraZeneca's new breast cancer therapy Etcamah claims landmark frontline approval in the EU, but its prospects in the US are less certain.

Welsh researchers secure funding for inherited breast cancer study

Researchers in Wales have secured funding to investigate new ways of treating inherited forms of breast cancer, thanks to new funding from Breast Cancer Now. Dr Christopher Staples at Bangor University has been awarded £169,622 to investigate how breast cancers with changes in the BRCA1 gene interact with the immune system, and how a specific […] The post Welsh researchers secure funding for inherited breast cancer study appeared first on Nation…

Scancell merges with Neuphoria after Merck axes trial; AstraZeneca breast cancer drug approved in EU

Scancell to merge into Neuphoria: Scancell plans to take over Neuphoria Therapeutics' Nasdaq listing {$NEUP} and change the ticker to SCLT. The company eyes up to $89 million in equity and ...

Astrazeneca secures EU approval for Etcamah in ER-positive breast cancer

Astrazeneca Plc (LON:AZN) has announced that Etcamah, in combination with a cyclin-dependent kinase (CDK) 4/6 inhibitor, has been approved in the European Union for the treatment of adult patients with estrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer upon detection of ESR1 mutation and without disease progression during 1st-line endocrine therapy in combination with a CDK4/6 inhibitor. Approval is based…